Stocks TelegraphStocks Telegraph
Stock Ideas

CDTX Company Profile and Key Details

NASDAQ : CDTX

Cidara Therapeutics

$221.38
00
At Close 4:00 PM
Not Actively Trading
64.21
BESG ScoreESG Rating

Price Chart

Stock Price Today

Cidara Therapeutics, Inc. (CDTX) stock remained unchanged at $221.38 a share on NASDAQ. The stock opened at $221.38, fluctuating between $221.38 to $221.38 during the session.

Stock Snapshot

221.38
Prev. Close
5.61B
Market Cap
221.38
Day Low
-19.76607142857143
P/E Ratio
-11.2
EPS (TTM)
-0.25
Cash Flow per Share
221.38
Open
25.36M
Number of Shares
221.38
Day High
74.08%
Free Float in %
-0.09
Book Value
2.69M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jan 06, 2026221.32221.41221.25221.382.65M
Jan 05, 2026221.11221.42221.07221.321.33M
Jan 02, 2026220.85221.10220.47221.031.43M
Dec 31, 2025220.75220.96220.75220.89509.82K
Dec 30, 2025220.60220.80220.40220.80612.64K
Dec 29, 2025220.80221.00220.41220.411.27M
Dec 26, 2025220.86221.00220.73220.80426.43K
Dec 24, 2025220.66221.00220.66220.86145.74K
Dec 23, 2025220.85220.91220.66220.86357.32K
Dec 22, 2025220.78221.00220.73220.85528.18K
Dec 19, 2025220.39221.02220.09220.801.82M
Dec 17, 2025220.11220.31219.91220.31559.43K
Dec 16, 2025219.96220.40219.96220.051.31M
Dec 15, 2025220.45220.45219.79220.101.27M
Dec 12, 2025220.29220.78220.15220.65551.1K
Dec 11, 2025219.86220.34219.81220.19745.18K
Dec 10, 2025220.20220.38219.60219.60805.64K
Dec 09, 2025220.06220.31219.76220.29824.56K
Dec 08, 2025220.54220.75219.82220.071.68M
Dec 05, 2025220.21220.90220.02220.36637.05K

Contact Details

San Diego, CA 92121

United States

https://www.cidara.com858 752 6170

About Company

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Company Information

Employees38
Beta1.53
Sales or Revenue$63.91M
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.36%, SMA50 19.61%, SMA200 164.56%). The stock’s 14-day RSI is 84.21 (overbought), while the ATR of 1.62 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.02% below its high and over 1354.53% above its low.

Dividend & Fair Value

Cidara Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $28.08. This means the shares are trading above this model’s fair value.

Shareholding & Insider Activity

Cidara Therapeutics, Inc. has 25.36 million shares outstanding. The public float is 18.78 million shares, elevated short interest at 8.49% of float. This equals 2.15 million shares. The short ratio is 5.14 days. Institutional investors hold 108.01% of the float. Insiders own 0.89%. RA CAPITAL MANAGEMENT, L.P. holds 3.37 million shares, BIOTECH TARGET N V has 2.30 million shares and Shah Preetam has 227.21 thousand shares. Over the past six months, insider transactions show net selling. They sold 10.43 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Cidara Therapeutics generated $63.91M in revenue, or $0.73 per share. Gross margin was 97.62%, operating margin -38.31%, and net profit margin -35.88%. Returns are negative, with ROA at -48.18% and ROE at 789.63%.
On valuation metrics, Cidara Therapeutics trades at a P/E of -18.63, P/S of 0.00 and P/B of 8.15. The current ratio is 4.62 and quick ratio is 4.62. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -35.29 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -67.01.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Cidara Therapeutics posted revenue of $63.91M, down slightly from $64.29M in the prior quarter. Gross profit was $62.38M (margin 97.62%). Operating income was - $24.48M (margin -38.3%). Net income was- $22.93M (EPS - $0.26).
The company ended the quarter with $32.73M in cash and short-term investments, a total debt of $1.32M, and net debt of - $31.41M. Total assets were $47.59M, with equity of - $2.90M. Financials further reflected weakness, with operating cash flow of - $28.47M, free cash flow of - $28.59M, and capital expenditures of - $118.00K.

Frequently Asked Questions

What is the current Cidara Therapeutics, Inc. (CDTX) stock price?
Cidara Therapeutics, Inc. (NASDAQ: CDTX) stock price is $221.38 in the last trading session. During the trading session, CDTX stock reached the peak price of $221.38 while $221.38 was the lowest point it dropped to. The percentage change in CDTX stock occurred in the recent session was 0% while the dollar amount for the price change in CDTX stock was $0.00.
CDTX's industry and sector of operation?
The NASDAQ listed CDTX is part of Biotechnology industry that operates in the broader Healthcare sector. Cidara Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of CDTX?
Dr. Taylor Sandison
Chief Medical Officer
Dr. Kevin M. Forrest Ph.D.
Founder and Chief Strategy Officer
Ms. Carol Waldo
Senior Vice President of Regulatory Affairs & Quality Assurance
Mr. James M. Balkovec
Senior Vice President of Research
Ms. Laura A. Navalta
Senior Vice President of Clinical Operations
Dr. Les Tari Ph.D.
Chief Scientific Officer
Mr. Shane M. Ward
Chief Operating Officer & Chief Legal Officer
Dr. Preetam Shah M.B.A., Ph.D.
Chief Financial Officer, Chief Bus. Officer & Principal Accounting Officer
Dr. Leslie Tari Ph.D.
Chief Scientific Officer
Ms. Allison Lewis CCP, SPHR
Senior Vice President of People & Culture
Dr. Jeffrey L. Stein Ph.D.
Pres, Chief Executive Officer & Executive Director
How CDTX did perform over past 52-week?
CDTX's closing price is 1,354.53% higher than its 52-week low of $15.22 where as its distance from 52-week high of $221.42 is -0.02%.
How many employees does CDTX have?
Number of CDTX employees currently stands at 38.
Link for CDTX official website?
Official Website of CDTX is: https://www.cidara.com
How do I contact CDTX?
CDTX could be contacted at phone 858 752 6170 and can also be accessed through its website. CDTX operates from 6310 Nancy Ridge Drive, San Diego, CA 92121, United States.
How many shares of CDTX are traded daily?
CDTX stock volume for the day was 2.69M shares. The average number of CDTX shares traded daily for last 3 months was 1.37M.
What is the market cap of CDTX currently?
The market value of CDTX currently stands at $5.61B with its latest stock price at $221.38 and 25.36M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph